Plain-English translation of NCT06706674 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called lumateperone to see if it can help reduce irritability in children and teens with autism spectrum disorder. Some participants will receive the medication at a higher dose, some at a lower dose, and some will receive a placebo (a pill with no active medicine). Researchers want to understand whether this treatment is safe and effective for managing irritability related to autism.
Irritability is a common and challenging symptom for many autistic children, and it can significantly affect their quality of life and family relationships. Currently, there are limited treatment options specifically designed to help with this symptom, so this study is exploring whether this medication could offer a new way to help.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will first go through a screening period of up to 2 weeks where doctors will confirm you meet all the requirements. Then you will take the medication (or placebo) once a day for 6 weeks, with regular clinic visits to check how you are doing and monitor for any side effects. About one week after finishing the medication, you will return for a final safety check-up. In total, the study lasts about 7–8 weeks.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States